亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

医学 内科学 胃肠病学 安慰剂 奥沙利铂 临床研究阶段 腺癌 临床终点 临床试验 外科 癌症 结直肠癌 病理 替代医学
作者
Zev A. Wainberg,Peter C. Enzinger,Yoon‐Koo Kang,Shukui Qin,Kensei Yamaguchi,Inho Kim,Anwaar Saeed,Sang Cheul Oh,Jin Li,Hacı Mehmet Türk,Alexandra Teixeira,Christophe Borg,Erika Hitre,Adrian Udrea,Giovanni Gerardo Cardellino,Raquel Guardeño Sanchez,Helen Collins,Siddhartha Mitra,Yingsi Yang,Daniel V.T. Catenacci
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (11): 1430-1440 被引量:215
标识
DOI:10.1016/s1470-2045(22)00603-9
摘要

Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas. In this study, we investigated efficacy and safety of the first-in-class, afucosylated, humanised IgG1 anti-fibroblast growth factor receptor 2 isoform IIb (FGFR2b) monoclonal antibody bemarituzumab with modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma.In the randomised, double-blind, placebo-controlled phase 2 trial (FIGHT), patients aged 18 years and older with HER2 non-positive, FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 were recruited from 144 clinical sites across 17 countries. Patients with previous treatment with any selective inhibitor of the FGF-FGFR pathway were excluded. Eligible patients were randomly assigned (1:1), using permuted-block randomisation (block size of four) and a central interactive voice-web-based response system, stratified by geographical region, previous treatment with curative intent, and administration of mFOLFOX6 while being screened for FGFR2b status, to either bemarituzumab (15 mg/kg of bodyweight) or matched placebo intravenously every 2 weeks. All patients also received mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and 5-fluorouracil as a 400 mg/m2 bolus followed by 2400 mg/m2 over approximately 46 h) intravenously every 2 weeks. Patients were given treatment until disease progression (defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1), unacceptable toxicity, withdrawal of consent, or death. The primary endpoint was progression-free survival in the intention-to-treat population (defined as all patients randomly assigned to treatment). Safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, NCT03694522, and is now complete.Between Nov 14, 2017, and May 8, 2020, 910 patients were screened and 155 were randomly assigned to the bemarituzumab (n=77) or placebo group (n=78). Median age was 60·0 years (IQR 51·0-67·0), 44 (28%) participants were women, 111 (72%) were men, 89 (57%) were Asian, and 61 (39%) were White. At the time of the primary analysis and at a median follow-up of 10·9 months (IQR 6·3-14·2), median progression-free survival was 9·5 months (95% CI 7·3-12·9) in the bemarituzumab group and 7·4 months (5·8-8·4) in the placebo group (hazard ratio [HR] 0·68 [95% CI 0·44-1·04; p=0·073). Common grade 3 or worse adverse events were decreased neutrophil count (23 [30%] of 76 in the bemarituzumab group vs 27 [35%] of 77 in the placebo group), cornea disorder (18 [24%] vs none), neutropenia (ten [13%] vs seven [9%]), stomatitis (seven [9%] vs one [1%]), and anaemia (six [8%] vs ten [13%]). Serious treatment-emergent adverse events were reported in 24 (32%) patients in the bemarituzumab group and 28 (36%) in the placebo group. Serious mFOLFOX6 treatment-related adverse events occurred in nine (12%) patients in the bemarituzumab group and in 15 (19%) patients in the placebo group. All-grade corneal events (adverse events of special interest) occurred in 51 (67%) patients in the bemarituzumab group and eight (10%) in the placebo group; grade 3 corneal events were reported only in 18 (24%) patients in the bemarituzumab group. Treatment-related deaths occurred in three patients in the bemarituzumab group (two due to sepsis, one due to pneumonia) and none in the placebo group.In this exploratory phase 2 study, despite no statistically significant improvement in progression-free survival, treatment with bemarituzumab showed promising clinical efficacy. Confirmatory phase 3 trials of bemarituzumab plus mFOLFOX6 powered to demonstrate statistical significance are being investigated in patients with previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma.Five Prime Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yc发布了新的文献求助10
13秒前
58秒前
58秒前
58秒前
我是笨蛋完成签到 ,获得积分10
1分钟前
欣喜的人龙完成签到 ,获得积分10
1分钟前
无花果的应助被荷兰香猪采纳,获得10
1分钟前
炙热芒果完成签到 ,获得积分10
1分钟前
1分钟前
荷兰香猪发布了新的文献求助10
1分钟前
传奇3的应助被药石无医采纳,获得10
1分钟前
2分钟前
Hello的应助被或大或小采纳,获得10
2分钟前
药石无医发布了新的文献求助10
2分钟前
传统的艳完成签到,获得积分10
2分钟前
荷兰香猪发布了新的文献求助10
2分钟前
zhangnan完成签到 ,获得积分10
2分钟前
荷兰香猪完成签到,获得积分10
2分钟前
2分钟前
lay完成签到,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
2分钟前
Owen的应助被科研通管家采纳,获得10
2分钟前
mimi完成签到 ,获得积分10
2分钟前
故意的梦琪完成签到,获得积分10
3分钟前
3分钟前
hugeyoung完成签到,获得积分10
3分钟前
盼盼发布了新的文献求助10
3分钟前
盼盼完成签到,获得积分10
4分钟前
ramsey33完成签到 ,获得积分10
4分钟前
酷酷云朵完成签到,获得积分10
4分钟前
4分钟前
帅气忻完成签到 ,获得积分10
4分钟前
4分钟前
SCI的芷蝶完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190148
求助须知:如何正确求助?哪些是违规求助? 9577257
关于积分的说明 21852289
捐赠科研通 7788541
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560044
邀请新用户注册赠送积分活动 2482880